University of Colorado School of Medic
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alvarez, Enrique Raya
NCT06529406: Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Recruiting
4
24
US
Ozanimod, Zeposia
University of Colorado, Denver
Relapsing Multiple Sclerosis
08/28
08/29
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
DURATIOM, NCT05294796: Efficacy and Safety of Antimicrobial Durations Treatment of Infections Associated With Osteosynthesis Material

Recruiting
3
364
Europe
Short course of antibiotherapy, Long course of antibiotherapy
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Infections
10/24
04/26
ASTARTÉ, NCT04478721: Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

Recruiting
3
334
Europe
Temocillin, Meropenem
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Network for Research in Infectious Diseases, SCReN Spanish research Network- CTU-HUVR
Bacteremia
03/25
12/25
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
NCT05671055: CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis

Completed
N/A
300
Europe, US
Custom study version of icompanion app
icometrix, Bristol-Myers Squibb
Multiple Sclerosis
12/23
12/23
RISEMS, NCT03586986: Risk Factors in Early Multiple Sclerosis

Recruiting
N/A
300
US
Brain MRI, Blood analysis, Bioscreen, Symbol Digit Modality Test (SDMT)
University of Colorado, Denver, Colorado School of Public Health
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome, Radiologically Isolated Syndrome
05/24
05/24
CAVS-MS, NCT04495556: Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Active, not recruiting
N/A
420
Canada, US
MRI
The Cleveland Clinic, National Institute of Neurological Disorders and Stroke (NINDS), University of Pennsylvania, Cedars-Sinai Medical Center, National Institutes of Health (NIH)
Multiple Sclerosis
06/25
06/25
Cooper, Joanna A
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
Muley, Suraj
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26

Download Options